Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention

BMC Cardiovascular Disorders

Volumn 9, Issue , 2009, Pages 48-

  Kullmann, Silke ^a   Binner, Priska ^a   Rackebrandt, Kirsten ^a   Huge, Andreas ^b   Haltern, Georg ^c   Lankisch, Mark ^c   Füth, Reiner ^c   von Hodenberg, Eberhard ^d   Bestehorn, Hans Peter ^e   Scheffold, Thomas ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c University Hospital Witten Herdecke   (Germany)

^d Heart Institute Lahr/Baden   (Germany)

^e UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ARGININE; EPOXIDE HYDROLASE; GENOMIC DNA; GUANOSINE; LYSINE; PLACEBO; VERAPAMIL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; RESTENOSIS; RISK FACTOR;

ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY RESTENOSIS; EPOXIDE HYDROLASES; EUROPE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VERAPAMIL;

EID: 70449640639     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-9-48     Document Type: Article

References (36)

1. McBride W, Lange RA, Hillis LD. Restenosis after successful coronary angioplasty. Pathophysiology and prevention. N Engl J Med 1988, 318(26):1734-1737.
2. Cohen DJ, Doucet M, Cutlip DE, Ho KK, Popma JJ, Kuntz RE. Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox?. Circulation 2001, 104(7):773-778. 10.1161/hc3201.094225, 11502701.
3. Loutfi M, Mulvihill NT, Boccalatte M, Farah B, Fajadet J, Marco J. Impact of restenosis and disease progression on clinical outcome after multivessel stenting in diabetic patients. Catheter Cardiovasc Interv 2003, 58(4):451-454. 10.1002/ccd.10455, 12652493.
4. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003, 361(9353):247-249. 10.1016/S0140-6736(03)12275-1, 12547552.
5. Rosanio S, Tocchi M, Patterson C, Runge MS. Prevention of restenosis after percutaneous coronary interventions: the medical approach. Thromb Haemost 1999, 82(Suppl 1):164-170.
6. Gruberg L, Waksman R, Satler LF, Pichard AD, Kent KM. Novel approaches for the prevention of restenosis. Expert Opin Investig Drugs 2000, 9(11):2555-2578. 10.1517/13543784.9.11.2555, 11060820.
7. Petrovic D, Peterlin B. Genetic markers of restenosis after coronary angioplasty and after stent implantation. Med Sci Monit 2005, 11(4):RA127-135.
8. Monraats PS, W RPA, Jukema JW. Genetic predictive factors in restenosis. Pathol Biol (Paris) 2004, 52(4):186-195.
9. Roman RJ, Maier KG, Sun CW, Harder DR, Alonso-Galicia M. Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids. Clin Exp Pharmacol Physiol 2000, 27(11):855-865. 10.1046/j.1440-1681.2000.03349.x, 11071299.
10. Sarkis A, Lopez B, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Curr Opin Nephrol Hypertens 2004, 13(2):205-214. 10.1097/00041552-200403000-00009, 15202615.
11. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996, 78(3):415-423.
12. Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 1996, 7(11):2364-2370.
13. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 2002, 39(2 Pt 2):690-694. 10.1161/hy0202.103788, 11882632.
14. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285(5431):1276-1279. 10.1126/science.285.5431.1276, 2720027, 10455056.
15. Campbell WB. New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. Trends Pharmacol Sci 2000, 21(4):125-127. 10.1016/S0165-6147(00)01472-3, 10740283.
16. Krotz F, Riexinger T, Buerkle MA, Nithipatikom K, Gloe T, Sohn HY, Campbell WB, Pohl U. Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol 2004, 24(3):595-600. 10.1161/01.ATV.0000116219.09040.8c, 14715644.
17. Larsen BT, Gutterman DD, Hatoum OA. Emerging role of epoxyeicosatrienoic acids in coronary vascular function. Eur J Clin Invest 2006, 36(5):293-300. 10.1111/j.1365-2362.2006.01634.x, 16634832.
18. Spiecker M, Liao JK. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 2005, 433(2):413-420. 10.1016/j.abb.2004.10.009, 15581597.
19. Spector AA, Fang X, Snyder GD, Weintraub NL. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 2004, 43(1):55-90. 10.1016/S0163-7827(03)00049-3, 14636671.
20. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000, 87(11):992-998.
21. Corenblum MJ, Wise VE, Georgi K, Hammock BD, Doris PA, Fornage M. Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat. Hypertension 2008, 51(2):567-573. 10.1161/HYPERTENSIONAHA.107.102160, 18086949.
22. Fornage M, Hinojos CA, Nurowska BW, Boerwinkle E, Hammock BD, Morisseau CH, Doris PA. Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension 2002, 40(4):485-490. 10.1161/01.HYP.0000032278.75806.68, 12364351.
23. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 2000, 275(51):40504-40510. 10.1074/jbc.M008106200, 11001943.
24. Luria A, Weldon SM, Kabcenell AK, Ingraham RH, Matera D, Jiang H, Gill R, Morisseau C, Newman JW, Hammock BD. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem 2007, 282(5):2891-2898. 10.1074/jbc.M608057200, 2040337, 17135253.
25. Fang X, Weintraub NL, McCaw RB, Hu S, Harmon SD, Rice JB, Hammock BD, Spector AA. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am J Physiol Heart Circ Physiol 2004, 287(6):H2412-2420. 10.1152/ajpheart.00527.2004, 15284062.
26. Wei Q, Doris PA, Pollizotto MV, Boerwinkle E, Jacobs DR, Siscovick DS, Fornage M. Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking. Atherosclerosis 2007, 190(1):26-34. 10.1016/j.atherosclerosis.2006.02.021, 16545818.
27. Burdon KP, Lehtinen AB, Langefeld CD, Carr JJ, Rich SS, Freedman BI, Herrington D, Bowden DW. Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study. Diab Vasc Dis Res 2008, 5(2):128-134. 10.3132/dvdr.2008.021, 18537101.
28. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, Zeldin DC. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 2006, 15(10):1640-1649. 10.1093/hmg/ddl085, 2040335, 16595607.
29. Sandberg M, Hassett C, Adman ET, Meijer J, Omiecinski CJ. Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms. J Biol Chem 2000, 275(37):28873-28881. 10.1074/jbc.M001153200, 10862610.
30. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, Maxwell JE, Hammock BD, Bradbury JA, Enayetallah AE, Zeldin DC, Grant DF. Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol 2003, 64(2):482-490. 10.1124/mol.64.2.482, 12869654.
31. Bestehorn HP, Neumann FJ, Buttner HJ, Betz P, Sturzenhofecker P, von Hodenberg E, Verdun A, Levai L, Monassier JP, Roskamm H. Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty (VESPA) Trial. J Am Coll Cardiol 2004, 43(12):2160-2165. 10.1016/j.jacc.2004.02.047, 15193674.
32. Srivastava PK, Sharma VK, Kalonia DS, Grant DF. Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure. Arch Biochem Biophys 2004, 427(2):164-169. 10.1016/j.abb.2004.05.003, 15196990.
33. Nakatani M, Takeyama Y, Shibata M, Yorozuya M, Suzuki H, Koba S, Katagiri T. Mechanisms of restenosis after coronary intervention: difference between plain old balloon angioplasty and stenting. Cardiovasc Pathol 2003, 12(1):40-48. 10.1016/S1054-8807(02)00135-7, 12598017.
34. Schwartz RS, Henry TD. Pathophysiology of coronary artery restenosis. Rev Cardiovasc Med 2002, 3(Suppl 5):S4-9.
35. Fornage M, Lee CR, Doris PA, Bray MS, Heiss G, Zeldin DC, Boerwinkle E. The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet 2005, 14(19):2829-2837. 10.1093/hmg/ddi315, 1343524, 16115816.
36. Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM, Anand S, Engert JC, Samani NJ, Schunkert H. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009, 41(3):334-41. 10.1038/ng.327, 2681011, 19198609.